Sutura, Inc.
OTC Bulletin Board : SUTU

Sutura, Inc.

October 14, 2005 07:38 ET

Sutura to Expand SuperStitch Product Line at TCT Convention in Washington, DC

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - Oct. 14, 2005) - Sutura®, Inc. ("Sutura")(OTCBB:SUTU), a California-based medical device company, announced today that the Company plans to roll out the sale of its new 8F 'As Simple As 1-2-3' SuperStitch suturing device at next week's TCT Convention in Washington, DC. The larger sized SuperStitch is intended to complement Sutura's 6F 'As Simple As 1-2-3' SuperStitch, and provide physicians with the ability to deploy the device in a larger number of cases.

"We wanted our new expanded sales team to have the larger-sized Superstitch product, with the 'As Simple As 1-2-3 design', when they meet with potential customers at the conference," said Anthony Nobles, CEO/President of Sutura. "In addition, our current customers have been asking for access to the 8F product and it was only natural that we introduce it as we ramp up our sales and marketing program at TCT."

"The introduction of the new 8F device immediately broadens our product line and sales potential as we introduce the SuperStitch to physicians and other health care professionals across the country," stated Tom Lindsey, Director of U.S. Sales and Marketing for Sutura. "The 'As Simple As 1-2-3' SuperStitich design is already getting a positive response in cath-labs, IR-labs and endovascular surgery departments. TCT is a great opportunity to put the product directly in front of thousands of our potential customers who will be attending next week's conference."

About Transcatheter Cardiovascular Therapeutics (TCT)

Transcatheter Cardiovascular Therapeutics (TCT), sponsored by the Cardiovascular Research Foundation (CRF), is the world's largest symposium for physicians and other health care professionals who specialize in the field of interventional vascular therapy. Held in the Washington Convention Center, this year's TCT spans five days, from Sunday afternoon, October 16 through Friday afternoon, October 21, 2005. As in previous years, numerous groundbreaking and pioneering innovations relevant to clinical practice will be introduced at the meeting. More information on this year's conference can be found at

About Sutura, Inc.

Sutura®, Inc. ( is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.

Within the United States the 8F & 6F SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch 8F & 6F is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may","appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information

  • Sutura, Inc.
    Barry Forward
    Corporate Communications
    (866) 676-8386